

CTI looks for projects that have:

- **Strong Project Rationale**
 - Demonstrated association between target biology, pathway and disease mechanism
 - Target validation as demonstrated by genetic or pharmacologic evidence
- **Therapeutic Area Opportunity**
 - Unmet medical needs, opportunity for novel therapeutic mechanism or modality in in-scope therapeutic areas
- **Therapeutic Drug Target**
 - Novel target, novel therapeutic strategy or new insight into target patient population
 - Defined target
 - Demonstrated cause/effect relationship to disease mechanism
 - Understanding of desired pharmacology
 - Tractability of target relative to drug modalities (eg monoclonal antibodies, peptides, proteins or, where applicable, small molecules), available reagents, assays and technologies
- **Project Feasibility**
 - Clear path to candidate development (biochemical/cell-free/cellular assays, disease models, preclinical testing, etc.)
 - Clear path to FIH clinical trial (approach for proof-of-mechanism in humans, accessible patient population, timeframe, safety issues, etc.)
- **Ability to Translate Basic Biological Research into the Clinic**
 - From molecular mechanism to therapeutic opportunity
 - Therapeutic strategies may include personalized medicine, patient stratification, molecular signatures, genetic associations, biomarkers

Platform technologies and exploratory research (eg target discovery, development of animal models, cell line models, indication expansion or mechanism of action for existing drugs) are generally out of scope for CTI. In-licensing opportunities are also generally out-of-scope although CTI may consider proposals for pre-existing drug candidates based upon discussions with the PI and TTO.